Edward Yu1, Miguel Ruiz-Canela2,3,4, Marta Guasch-Ferré1,3,4, Yan Zheng1, Estefania Toledo2,3,4, Clary B Clish5, Jordi Salas-Salvadó4,6, Liming Liang7, Dong D Wang1, Dolores Corella4,8, Montse Fitó4,9, Enrique Gómez-Gracia10, José Lapetra4,11, Ramón Estruch4,12, Emilio Ros4,13, Montserrat Cofán4,13, Fernando Arós4,14, Dora Romaguera4,15, Lluis Serra-Majem4,16, Jose V Sorlí4,9, Frank B Hu1,17,18, Miguel A Martinez-Gonzalez19,2,3,4. 1. Departments of Nutrition. 2. Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain. 3. Navarra Institute for Health Research, Pamplona, Spain. 4. Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. 5. Broad Institute of MIT and Harvard University, Cambridge, MA. 6. Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain. 7. Biostatistics, and. 8. Department of Preventive Medicine, University of Valencia, Valencia, Spain. 9. Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Barcelona, Spain. 10. Department of Preventive Medicine, University of Málaga, Málaga, Spain. 11. Department of Family Medicine, Unit Research, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain. 12. Department of Internal Medicine Institut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clinic, and. 13. Lipid Clinic, Department of Endocrinology and Nutrition and University of Barcelona, Barcelona, Spain. 14. Department of Cardiology, University Hospital of Álava, Vitoria, Spain. 15. Health Research Institute of Palma, University Hospital Son Espases, Palma de Mallorca, Spain. 16. Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain; and. 17. Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA. 18. Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 19. Departments of Nutrition, mamartinez@unav.es.
Abstract
Background: During development of cardiovascular disease (CVD), interferon-γ-mediated inflammation accelerates degradation of tryptophan into downstream metabolites. A Mediterranean diet (MedDiet) consisting of a high intake of extra-virgin olive oil (EVOO), nuts, fruits, vegetables, and cereals has been demonstrated to lower the risk of CVD. The longitudinal relation between tryptophan and its downstream metabolites and CVD in the context of a MedDiet is unstudied.Objective: We sought to investigate the relation between metabolites in the tryptophan-kynurenine pathway and CVD in the context of a MedDiet pattern. Methods: We used a case-cohort design nested in the Prevención con Dieta Mediterránea randomized controlled trial. There were 231 CVD cases (stroke, myocardial infarction, cardiovascular death) among 985 participants over a median of 4.7 y of follow-up [mean ± SD age: 67.6 ± 6.1 y; 53.7% women; mean ± SD body mass index (in kg/m2): 29.7 ± 3.7]. We assessed plasma tryptophan, kynurenine, kynurenic acid, 3-hydroxyanthranilic acid, and quinolinic acid concentrations at baseline and after 1 y of intervention with a MedDiet. We combined these metabolites in a kynurenine risk score (KRS) by weighting each metabolite by the adjusted coefficient of its associations with CVD. Cox models were used in the primary analysis. Results: Increases in tryptophan after 1 y were associated with a lower risk of composite CVD (HR per SD: 0.79; 95% CI: 0.63, 0.98). The baseline kynurenic acid concentration was associated with a higher risk of myocardial infarction and coronary artery disease death but not stroke. A higher KRS was more strongly associated with CVD in the control group than in the 2 intervention groups (P-interaction = 0.003). Adjustment for changes in plasma tryptophan attenuated the inverse association between MedDiet+EVOO and CVD.Conclusions: An increase in the plasma tryptophan concentration was significantly associated with a decreased risk of CVD. A MedDiet may counteract the deleterious effects of a high kynurenine risk score.
Background: During development of cardiovascular disease (CVD), interferon-γ-mediated inflammation accelerates degradation of tryptophan into downstream metabolites. A Mediterranean diet (MedDiet) consisting of a high intake of extra-virgin olive oil (EVOO), nuts, fruits, vegetables, and cereals has been demonstrated to lower the risk of CVD. The longitudinal relation between tryptophan and its downstream metabolites and CVD in the context of a MedDiet is unstudied.Objective: We sought to investigate the relation between metabolites in the tryptophan-kynurenine pathway and CVD in the context of a MedDiet pattern. Methods: We used a case-cohort design nested in the Prevención con Dieta Mediterránea randomized controlled trial. There were 231 CVD cases (stroke, myocardial infarction, cardiovascular death) among 985 participants over a median of 4.7 y of follow-up [mean ± SD age: 67.6 ± 6.1 y; 53.7% women; mean ± SD body mass index (in kg/m2): 29.7 ± 3.7]. We assessed plasma tryptophan, kynurenine, kynurenic acid, 3-hydroxyanthranilic acid, and quinolinic acid concentrations at baseline and after 1 y of intervention with a MedDiet. We combined these metabolites in a kynurenine risk score (KRS) by weighting each metabolite by the adjusted coefficient of its associations with CVD. Cox models were used in the primary analysis. Results: Increases in tryptophan after 1 y were associated with a lower risk of composite CVD (HR per SD: 0.79; 95% CI: 0.63, 0.98). The baseline kynurenic acid concentration was associated with a higher risk of myocardial infarction and coronary artery disease death but not stroke. A higher KRS was more strongly associated with CVD in the control group than in the 2 intervention groups (P-interaction = 0.003). Adjustment for changes in plasma tryptophan attenuated the inverse association between MedDiet+EVOO and CVD.Conclusions: An increase in the plasma tryptophan concentration was significantly associated with a decreased risk of CVD. A MedDiet may counteract the deleterious effects of a high kynurenine risk score.
Authors: Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa Maria Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel Angel Muñoz; José V Sorlí; José Alfredo Martínez; Miguel Angel Martínez-González Journal: N Engl J Med Date: 2013-02-25 Impact factor: 91.245
Authors: Lei Zhang; Olga Ovchinnikova; Andreas Jönsson; Anna M Lundberg; Martin Berg; Göran K Hansson; Daniel F J Ketelhuth Journal: Eur Heart J Date: 2012-06-18 Impact factor: 29.983
Authors: Edward Yu; Christopher Papandreou; Miguel Ruiz-Canela; Marta Guasch-Ferre; Clary B Clish; Courtney Dennis; Liming Liang; Dolores Corella; Montserrat Fitó; Cristina Razquin; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Estefania Toledo; Lluis Serra-Majem; José V Sorlí; Frank B Hu; Miguel A Martinez-Gonzalez; Jordi Salas-Salvado Journal: Clin Chem Date: 2018-06-08 Impact factor: 8.327
Authors: Luis E Zambrana; Annika M Weber; Erica C Borresen; Iman Zarei; Johann Perez; Claudia Perez; Iker Rodríguez; Sylvia Becker-Dreps; Lijuan Yuan; Samuel Vilchez; Elizabeth P Ryan Journal: Curr Dev Nutr Date: 2021-07-21
Authors: Qibin Qi; Simin Hua; Clary B Clish; Justin M Scott; David B Hanna; Tao Wang; Sabina A Haberlen; Sanjiv J Shah; Marshall J Glesby; Jason M Lazar; Robert D Burk; Howard N Hodis; Alan L Landay; Wendy S Post; Kathryn Anastos; Robert C Kaplan Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Venkatesh L Murthy; Ravi V Shah; Jared P Reis; Alexander R Pico; Robert Kitchen; Joao A C Lima; Donald Lloyd-Jones; Norrina B Allen; Mercedes Carnethon; Gregory D Lewis; Matthew Nayor; Ramachandran S Vasan; Jane E Freedman; Clary B Clish Journal: Circulation Date: 2020-10-19 Impact factor: 29.690